MAPT and Alzheimer disease: Similar to previous findings on the diagnostic accuracy of individual CSF biomarkers, we found that CSF Aβ1-42 discriminated better between those with AD dementia and Aβ-PET–negative controls than CSF tau biomarkers,19 whereas CSF tau biomarkers discriminated better between AD and non-AD dementia cases than CSF Aβ1-42.